How effective is lacosamide versus other aeds?

How effective is lacosamide compared with other seizure drugs?

Lacosamide reduces seizure frequency by at least 50 percent in 30-40 percent of patients with focal epilepsy who add it to existing treatment. The same figure for lamotrigine, levetiracetam, and oxcarbazepine ranges from 30 to 50 percent when used as add-on therapy.

What head-to-head data exist for lacosamide?

No large randomized trials directly compare lacosamide with newer agents such as brivaracetam or perampanel. Indirect network meta-analyses find similar overall responder rates, yet levetiracetam appears slightly higher in some reports. Lacosamide maintains efficacy through 3-5 years of open-label follow-up, similar to other second-generation drugs.

When does lacosamide’s patent expire?

Lacosamide’s composition-of-matter patent expires in 2025 in the United States. Several generic manufacturers have filed abbreviated new drug applications. Generic versions are expected to reach pharmacies once the patent expires.

What side effects do patients report with lacosamide?

Dizziness and somnolence occur in 10-20 percent of patients. Heart-rhythm changes, including PR-interval prolongation, require caution in people with heart-block history. Compared with topiramate and zonisamide, lacosamide shows lower rates of cognitive dulling and weight loss.

How does the price of lacosamide differ from competitors?

Brand-name Vimpat costs roughly $900-1100 per month. Many insurance plans cover it under tier 3 or 4. After generics launch, price drops of 70-80 percent are typical.